Keywords: Nabi Biopharma, NicVAX, Smoking cessation, GlaxoSmithKline

Nabi plunges as NicVAX flops in Ph III trial

Article | 19 July 2011

US drug developer Nabi Biopharmaceuticals (Nasdaq: NABI) saw its shares nose-dive 70% to $1.76 in early trading yesterday, after the company revealed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

GlaxoSmithKline

Nabi Biopharmaceuticals

Go to company listing